Ranibizumab in patients with neovascular age-related macular degeneration in real-world clinical settings in France: 1-year data from the LUMINOUS (TM) study

Purpose : LUMINOUS™ (NCT01318941; initiated March 2011) is the largest, prospective, observational, global study in the field of medical retina. LUMINOUS™ is an ongoing 5-year study that is designed to evaluate the long-term safety, effectiveness, treatment patterns, and health-related quality of life associated with ranibizumab (RBZ) 0.5 mg treatment across all approved indications in 30,000 patients from routine clinical practice. We present the 1-year data from the French patients included in LUMINOUS™. Methods : Overall, 17, 545 adult patients with neovascular age-related macular degeneration (nAMD) were enrolled before March 2014; of these 9125 adult nAMD patients with a potential for …

Traitements médicaux de la DMLA

National audience

Session inflammation : Cas cliniques d’allergie et de syndrome sec, session rétine : Pourquoi un DR ne récupère pas ? - Session diabète : Cas clinique de diabète

National audience

Diabète : Grandes modalités de dépistage